Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

MRI hip findings in asymptomatic professional rugby players, ballet dancers, and age-matched controls.

Blankenstein T, Grainger A, Dube B, Evans R, Robinson P.

Clin Radiol. 2019 Sep 30. pii: S0009-9260(19)30550-1. doi: 10.1016/j.crad.2019.08.024. [Epub ahead of print]

PMID:
31582172
2.

SigsPack, a package for cancer mutational signatures.

Schumann F, Blanc E, Messerschmidt C, Blankenstein T, Busse A, Beule D.

BMC Bioinformatics. 2019 Sep 2;20(1):450. doi: 10.1186/s12859-019-3043-7.

3.

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.

Penter L, Dietze K, Ritter J, Lammoglia Cobo MF, Garmshausen J, Aigner F, Bullinger L, Hackstein H, Wienzek-Lischka S, Blankenstein T, Hummel M, Dornmair K, Hansmann L.

Oncoimmunology. 2019 Mar 24;8(6):e1586409. doi: 10.1080/2162402X.2019.1586409. eCollection 2019.

4.

Interferon-γ Receptor Signaling in Dendritic Cells Restrains Spontaneous Proliferation of CD4+ T Cells in Chronic Lymphopenic Mice.

Knop L, Frommer C, Stoycheva D, Deiser K, Kalinke U, Blankenstein T, Kammertoens T, Dunay IR, Schüler T.

Front Immunol. 2019 Feb 7;10:140. doi: 10.3389/fimmu.2019.00140. eCollection 2019.

5.

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.

Çakmak-Görür N, Radke J, Rhein S, Schumann E, Willimsky G, Heppner FL, Blankenstein T, Pezzutto A.

Leukemia. 2019 Apr;33(4):1039-1043. doi: 10.1038/s41375-018-0330-7. Epub 2019 Jan 3. No abstract available.

6.

Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.

Poncette L, Chen X, Lorenz FK, Blankenstein T.

J Clin Invest. 2019 Jan 2;129(1):324-335. doi: 10.1172/JCI120391. Epub 2018 Dec 10.

7.

Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice.

Hoser D, Schön C, Loddenkemper C, Lohneis P, Kühl AA, Sommermann T, Blankenstein T, Willimsky G.

Blood. 2018 Aug 30;132(9):924-934. doi: 10.1182/blood-2018-02-834036. Epub 2018 Jul 12.

PMID:
30002144
8.

Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.

Gavvovidis I, Leisegang M, Willimsky G, Miller N, Nghiem P, Blankenstein T.

Clin Cancer Res. 2018 Aug 1;24(15):3644-3655. doi: 10.1158/1078-0432.CCR-17-2661. Epub 2018 Apr 18.

9.

ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice.

Schmidt K, Keller C, Kühl AA, Textor A, Seifert U, Blankenstein T, Willimsky G, Kloetzel PM.

Cancer Res. 2018 Jun 15;78(12):3243-3254. doi: 10.1158/0008-5472.CAN-17-1946. Epub 2018 Mar 20.

10.

[Changes to cervical cancer screening in Germany].

Starrach T, Gallwas J, Blankenstein T, Mahner S, Dannecker C.

MMW Fortschr Med. 2018 Feb;160(2):46-51. doi: 10.1007/s15006-018-0152-6. Review. German. No abstract available.

PMID:
29417509
11.

A Transgenic Dual-Luciferase Reporter Mouse for Longitudinal and Functional Monitoring of T Cells In Vivo.

Szyska M, Herda S, Althoff S, Heimann A, Russ J, D'Abundo D, Dang TM, Durieux I, Dörken B, Blankenstein T, Na IK.

Cancer Immunol Res. 2018 Jan;6(1):110-120. doi: 10.1158/2326-6066.CIR-17-0256. Epub 2017 Dec 19.

12.

Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversity.

Chen X, Poncette L, Blankenstein T.

J Exp Med. 2017 Nov 6;214(11):3417-3433. doi: 10.1084/jem.20161784. Epub 2017 Aug 23.

13.

The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy.

Anders K, Kershaw O, Larue L, Gruber AD, Blankenstein T.

Int J Cancer. 2017 Dec 15;141(12):2551-2561. doi: 10.1002/ijc.31009. Epub 2017 Aug 31.

14.

CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.

Herrmann A, Lahtz C, Nagao T, Song JY, Chan WC, Lee H, Yue C, Look T, Mülfarth R, Li W, Jenkins K, Williams J, Budde LE, Forman S, Kwak L, Blankenstein T, Yu H.

Cancer Res. 2017 Sep 15;77(18):5118-5128. doi: 10.1158/0008-5472.CAN-16-0342. Epub 2017 Jul 17.

15.

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk.

Kunert A, Obenaus M, Lamers CHJ, Blankenstein T, Debets R.

Clin Cancer Res. 2017 Oct 15;23(20):6012-6020. doi: 10.1158/1078-0432.CCR-17-1012. Epub 2017 Jun 23. Review.

16.

Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations.

Kost BP, Hofmann J, Stoellnberger S, Bergauer F, Blankenstein T, Alba-Alejandre I, Stein A, Stuckart C, Weizsäcker K, Mylonas I, Mahner S, Gingelmaier A.

Oncol Lett. 2017 Apr;13(4):2495-2501. doi: 10.3892/ol.2017.5714. Epub 2017 Feb 10.

17.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T.

Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26.

18.

Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.

Textor A, Schmidt K, Kloetzel PM, Weißbrich B, Perez C, Charo J, Anders K, Sidney J, Sette A, Schumacher TN, Keller C, Busch DH, Seifert U, Blankenstein T.

J Exp Med. 2017 Feb;214(2):567. doi: 10.1084/jem.2016063601122017c. Epub 2017 Jan 17. No abstract available.

19.

Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.

Miller NJ, Church CD, Dong L, Crispin D, Fitzgibbon MP, Lachance K, Jing L, Shinohara M, Gavvovidis I, Willimsky G, McIntosh M, Blankenstein T, Koelle DM, Nghiem P.

Cancer Immunol Res. 2017 Feb;5(2):137-147. doi: 10.1158/2326-6066.CIR-16-0210. Epub 2017 Jan 16.

20.

Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.

Textor A, Schmidt K, Kloetzel PM, Weißbrich B, Perez C, Charo J, Anders K, Sidney J, Sette A, Schumacher TN, Keller C, Busch DH, Seifert U, Blankenstein T.

J Exp Med. 2016 Oct 17;213(11):2333-2348. Epub 2016 Oct 3. Erratum in: J Exp Med. 2017 Feb;214(2):567.

21.

Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells.

Deiser K, Stoycheva D, Bank U, Blankenstein T, Schüler T.

PLoS One. 2016 Jul 22;11(7):e0159690. doi: 10.1371/journal.pone.0159690. eCollection 2016.

22.

Expression of Activin During and After Chemotherapy in Peripheral Blood of Patients with Primary Breast Cancer.

Jueckstock J, Burkhardt N, Kuhn C, Blankenstein T, Mahner S, Schindlbeck C, Janni W, Rack B, Mylonas I.

Anticancer Res. 2016 May;36(5):2153-9.

PMID:
27127117
23.

Receptor combinations hone T-cell therapy.

Blankenstein T.

Nat Biotechnol. 2016 Apr;34(4):389-91. doi: 10.1038/nbt.3539. No abstract available.

PMID:
27054992
24.

Targeting human melanoma neoantigens by T cell receptor gene therapy.

Leisegang M, Kammertoens T, Uckert W, Blankenstein T.

J Clin Invest. 2016 Mar 1;126(3):854-8. doi: 10.1172/JCI83465. Epub 2016 Jan 25.

25.
26.

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Obenaus M, Leitão C, Leisegang M, Chen X, Gavvovidis I, van der Bruggen P, Uckert W, Schendel DJ, Blankenstein T.

Nat Biotechnol. 2015 Apr;33(4):402-7. doi: 10.1038/nbt.3147. Epub 2015 Mar 16.

PMID:
25774714
27.

Targeting cancer-specific mutations by T cell receptor gene therapy.

Blankenstein T, Leisegang M, Uckert W, Schreiber H.

Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Review.

28.

Point-of-care (POC) diagnosis of bacterial vaginosis (BV) using VGTest™ ion mobility spectrometry (IMS) in a routine ambulatory care gynecology clinic.

Blankenstein T, Lytton SD, Leidl B, Atweh E, Friese K, Mylonas I.

Arch Gynecol Obstet. 2015 Aug;292(2):355-62. doi: 10.1007/s00404-014-3613-x. Epub 2015 Feb 1.

PMID:
25638448
29.

Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.

Perez C, Jukica A, Listopad JJ, Anders K, Kühl AA, Loddenkemper C, Blankenstein T, Charo J.

Int J Cancer. 2015 Jul 15;137(2):359-71. doi: 10.1002/ijc.29401. Epub 2015 Jan 28.

30.

Function and regulation of MTA1 and MTA3 in malignancies of the female reproductive system.

Brüning A, Blankenstein T, Jückstock J, Mylonas I.

Cancer Metastasis Rev. 2014 Dec;33(4):943-51. doi: 10.1007/s10555-014-9520-6. Review.

PMID:
25319202
31.

Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.

Textor A, Listopad JJ, Wührmann LL, Perez C, Kruschinski A, Chmielewski M, Abken H, Blankenstein T, Charo J.

Cancer Res. 2014 Dec 1;74(23):6796-805. doi: 10.1158/0008-5472.CAN-14-0079. Epub 2014 Oct 8.

32.

Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.

Flörcken A, Grau M, Wolf A, Weilemann A, Kopp J, Dörken B, Blankenstein T, Pezzutto A, Lenz P, Lenz G, Westermann J.

Int J Cancer. 2015 Apr 15;136(8):1814-26. doi: 10.1002/ijc.29230. Epub 2014 Sep 30.

33.

Sagittal computed tomogram of the neck with bone windows.

Gibson LM, Blankenstein TN.

BMJ. 2014 Jul 8;349:g4444. doi: 10.1136/bmj.g4444. No abstract available.

PMID:
25005795
34.

Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells.

Pinto S, Sommermeyer D, Michel C, Wilde S, Schendel D, Uckert W, Blankenstein T, Kyewski B.

Eur J Immunol. 2014 Sep;44(9):2811-21. doi: 10.1002/eji.201444499. Epub 2014 Aug 18.

35.

IL-13 but not IL-4 signaling via IL-4Rα protects mice from papilloma formation during DMBA/TPA two-step skin carcinogenesis.

Rothe M, Quarcoo D, Chashchina AA, Bozrova SV, Qin Z, Nedospasov SA, Blankenstein T, Kammertoens T, Drutskaya MS.

Cancer Med. 2013 Dec;2(6):815-25. doi: 10.1002/cam4.145. Epub 2013 Oct 22.

36.

High-throughput identification of antigen-specific TCRs by TCR gene capture.

Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, Bresser K, Nieuwland M, Schotte R, Michels S, Gomez-Eerland R, Jahn L, Hombrink P, Legrand N, Shu CJ, Mamedov IZ, Velds A, Blank CU, Haanen JB, Turchaninova MA, Kerkhoven RM, Spits H, Hadrup SR, Heemskerk MH, Blankenstein T, Chudakov DM, Bendle GM, Schumacher TN.

Nat Med. 2013 Nov;19(11):1534-41. doi: 10.1038/nm.3359. Epub 2013 Oct 13.

PMID:
24121928
37.

Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast-embryonic stem cell fusion.

Li L, Blankenstein T.

Nat Protoc. 2013 Aug;8(8):1567-82. doi: 10.1038/nprot.2013.093. Epub 2013 Jul 18.

PMID:
23868074
38.

Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation.

Hess Michelini R, Manzo T, Sturmheit T, Basso V, Rocchi M, Freschi M, Listopad J, Blankenstein T, Bellone M, Mondino A.

Cancer Res. 2013 Aug 1;73(15):4641-52. doi: 10.1158/0008-5472.CAN-12-3464. Epub 2013 Jun 7.

39.

Medical provision in forward locations in Afghanistan: the experiences of General Duties Medical Officers on Op HERRICK 15.

Gumbley AE, Claydon MA, Blankenstein TN, Fell TH.

J R Army Med Corps. 2013 Jun;159(2):68-72. doi: 10.1136/jramc-2013-000036. Epub 2013 Mar 20.

PMID:
23720586
40.

It's the peptide-MHC affinity, stupid.

Kammertoens T, Blankenstein T.

Cancer Cell. 2013 Apr 15;23(4):429-31. doi: 10.1016/j.ccr.2013.04.004.

41.

Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens.

Zhang J, Chen L, Liu X, Kammertoens T, Blankenstein T, Qin Z.

Cancer Res. 2013 May 1;73(9):2770-81. doi: 10.1158/0008-5472.CAN-12-3022. Epub 2013 Mar 28.

42.

Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T.

J Clin Invest. 2013 Mar;123(3):1032-43. doi: 10.1172/JCI64742. Epub 2013 Feb 1.

43.

Fas expression by tumor stroma is required for cancer eradication.

Listopad JJ, Kammertoens T, Anders K, Silkenstedt B, Willimsky G, Schmidt K, Kuehl AA, Loddenkemper C, Blankenstein T.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2276-81. doi: 10.1073/pnas.1218295110. Epub 2013 Jan 22.

44.

Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer.

Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G.

Blood. 2013 Mar 7;121(10):1740-8. doi: 10.1182/blood-2012-06-436568. Epub 2013 Jan 10.

PMID:
23305737
45.

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, Willimsky G, Stief CG, Hofstetter A, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Mol Med. 2013 Feb 8;18:1499-508. doi: 10.2119/molmed.2012.00221.

46.

Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes.

Anders K, Blankenstein T.

Clin Cancer Res. 2013 Jan 15;19(2):320-6. doi: 10.1158/1078-0432.CCR-12-3017. Epub 2012 Nov 29. Review.

47.

Development of a postsurgical patient-reported outcome instrument for women with vulvar neoplasia.

Senn B, Mueller MD, Hasenburg A, Blankenstein T, Kammermann B, Hartmann A, Donovan H, Eicher M, Spirig R, Engberg S.

Oncol Nurs Forum. 2012 Nov;39(6):E489-98. doi: 10.1188/12.ONF.E489-E498.

PMID:
23107862
48.

Differences in serum cytokine levels between wild type mice and mice with a targeted mutation suggests necessity of using control littermates.

Briesemeister D, Friese C, Isern CC, Dietz E, Blankenstein T, Thoene-Reineke C, Kammertoens T.

Cytokine. 2012 Dec;60(3):626-33. doi: 10.1016/j.cyto.2012.07.019. Epub 2012 Aug 17.

PMID:
22902947
49.

Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.

Gerbitz A, Sukumar M, Helm F, Wilke A, Friese C, Fahrenwaldt C, Lehmann FM, Loddenkemper C, Kammertoens T, Mautner J, Schmitt CA, Blankenstein T, Bornkamm GW.

PLoS One. 2012;7(3):e34552. doi: 10.1371/journal.pone.0034552. Epub 2012 Mar 30.

50.

The determinants of tumour immunogenicity.

Blankenstein T, Coulie PG, Gilboa E, Jaffee EM.

Nat Rev Cancer. 2012 Mar 1;12(4):307-13. doi: 10.1038/nrc3246. Review.

Supplemental Content

Loading ...
Support Center